Companies Cryptocurrencies
Nabriva Therapeutics PLC
Nabriva Therapeutics PLC
Exchange: Nasdaq Global Select
IPO Date: 18/09/2015
CEO: Mr. Theodore Schroeder
Biotechnology Healthcare 🔗
  • NBRV
  • 1.26
  • 62671012
    market cap
  • 0.08000004
If you bought

shares of Nabriva Therapeutics PLC (NBRV) on
You would have made
Old Price $12 Current Price $12

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. The firm is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Address: 56 Fitzwilliam Square North DUBLIN 1

Stay updated.